Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. is dated November 15, 2023. The report serves to incorporate by reference two press releases: one regarding a regulatory appeal to the U.S. FDA and another detailing financial results for the nine months ended September 30, 2023.
Key Financial Metrics
The filing text incorporates a press release containing financial results for the nine months ended September 30, 2023, but does not explicitly state specific values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this Form 6-K document. Investors must refer to the incorporated Exhibit 99.2 for these specific figures.
Material Changes and Operational Highlights
- Regulatory Action: The Company filed an appeal with the U.S. FDA requesting a review of its De Novo classification for the ProSense® system in early-stage breast cancer.
- Financial Reporting: The Company reported financial results for the nine months ended September 30, 2023, alongside an update on recent operational highlights.
Guidance, Outlook, and Risks
The filing incorporates "Forward Looking Statements" from the press release regarding the FDA appeal. The primary contingency identified is the outcome of the FDA's review of the De Novo classification for ProSense® in early-stage breast cancer. No specific financial guidance or numerical outlook is provided in the text of this filing.
Investor Verification Checklist
- Review Exhibit 99.2 for specific revenue, net loss, and cash position figures for the nine months ended September 30, 2023.
- Verify the status and potential timeline of the FDA appeal regarding the ProSense® De Novo classification.
- Assess the impact of the regulatory appeal on the Company's commercialization strategy for early-stage breast cancer.